Möchten Sie immer auf dem neuesten Stand bleiben?

Chemomab announced financial and operating results for the first quarter and provided a corporate update, including 4 presentations at DDW and EASL 2026.

Dynacor Group Inc. announces its unaudited financial and operational results for the first quarter ended March 31, 2026.

Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansionContinued advancement of pharmaceutical pipeline, medical affairs initiatives and international...

Global Genomic Medicine Market to reach USD 123 billion by 2035, driven by rising cancer cases and growing adoption of precision medicine.

Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV® study presented today at ASGCT 2026 Annual Meeting along with initial...

Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 millionInvivyd in vitro data showed continued...

MONTREAL, May 14, 2026 (GLOBE NEWSWIRE) -- Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the first quarter of fiscal 2026. Highlights Financial...

Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in...

Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses...

Record Quarterly Revenues of $1.04 Billion, a 105% Increase from a Year Ago Excluding Bowers Acquisition, Revenues (non-GAAP) Grew by 57% from a Year Ago1 Quarterly Adjusted EBITDA (non-GAAP)...